🏢 官网IRNTLACodex · 实盘不做把握 3/10
北京时间·🕒 发布 20:00:00(美东 08:00)·⟳ 抓取 20:04:11 +4m11s·⚡ 决策 07-30 20:05:16 +1m05s·88.9 天前
Intellia宣布将于8月6日召开电话会议
该公告仅为公司电话会议日程通知，未披露临床数据、监管进展、融资、合作或业绩 surprise。
📄 原文NTLA↗ 原文
Intellia Therapeutics conference call. A replay of the call will be available for approximately 90 days on the Events p…
不做 Intellia Therapeutics（NTLA.US）
只是电话会议预告，没有临床数据、监管审批、商业合作或财务 surprise，方向和edge都不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 low · price-in 风险 low ↗
关键理由
- 该公告仅为公司电话会议日程通知，未披露临床数据、监管进展、融资、合作或业绩 surprise。
主要风险
- 若8月6日会议实际披露重大临床或监管信息，应由届时新信号重新研判。
原文全文
展开原文 · 1,036 字
Intellia Therapeutics
conference call.
A replay of the call will be available for approximately 90 days on the Events page in the Investors & Media section of Intellia’s website,
www.intelliatx.com
.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at
intelliatx.com
and follow us
@intelliatx
.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com
conference call.
A replay of the call will be available for approximately 90 days on the Events page in the Investors & Media section of Intellia’s website,
www.intelliatx.com
.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at
intelliatx.com
and follow us
@intelliatx
.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。